Literature DB >> 21621854

C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia.

Mounir H Fawzi1, Mohab M Fawzi, Maggie M Fawzi, Nagwa S Said.   

Abstract

Despite the growing research interest in the role of immunological markers in schizophrenia, few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. In this cross-sectional case-control study, a sample of 200 antipsychotic-free male Egyptian schizophrenia patients was assessed by the Positive and Negative Syndrome Scale (PANSS) and compared with 200 healthy controls as regards serum hs-CRP level using an immunoturbidimetric method. CRP level for patients (geometric mean=3.3 mg/L) was significantly (P=0.000) higher than that for controls (geometric mean=1.4 mg/L). PANSS scores and patients' data, which significantly correlated with serum hs-CRP level, were entered into a stepwise multiple regression analysis. Results of this analysis showed that PANSS negative symptom score was second only to the waist circumference, with which they explained 54.7 % of the variation in serum hs-CRP. Comparable results were obtained when patients, controls and the relevant confounders were included in one multivariate analysis. We concluded that in Egyptian men, waist circumference and schizophrenia diagnosis are strong predictors of raised CRP level independent of a number of potentially confounding variables. In antipsychotic-free patients, CRP level is higher than in healthy controls and is positively correlated with the severity of the psychopathology as measured by PANSS. This relationship is especially notable in negative, but not positive symptoms.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621854     DOI: 10.1016/j.psychres.2011.05.010

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  28 in total

1.  Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study.

Authors:  Marie Kim Wium-Andersen; David Dynnes Ørsted; Børge Grønne Nordestgaard
Journal:  Schizophr Bull       Date:  2013-08-31       Impact factor: 9.306

2.  Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.

Authors:  Xueqin Song; Xiaoduo Fan; Xue Li; Wei Zhang; Jinsong Gao; Jingping Zhao; Amy Harrington; Douglas Ziedonis; Luxian Lv
Journal:  Psychopharmacology (Berl)       Date:  2013-12-14       Impact factor: 4.530

Review 3.  Late-onset schizophrenia: do recent studies support categorizing LOS as a subtype of schizophrenia?

Authors:  Jeanne E Maglione; Scot E Thomas; Dilip V Jeste
Journal:  Curr Opin Psychiatry       Date:  2014-05       Impact factor: 4.741

4.  Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.

Authors:  Ted Boozalis; Sridevi Devaraj; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2019-03

5.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.

Authors:  B S Fernandes; J Steiner; H-G Bernstein; S Dodd; J A Pasco; O M Dean; P Nardin; C-A Gonçalves; M Berk
Journal:  Mol Psychiatry       Date:  2015-07-14       Impact factor: 15.992

6.  Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort.

Authors:  G Fond; F Berna; M Andrianarisoa; O Godin; M Leboyer; L Brunel; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; H Denizot; C Dubertret; J Dubreucq; C Faget; F Gabayet; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Richieri; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; F Schürhoff
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-25       Impact factor: 5.270

7.  Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.

Authors:  Meijuan Li; Yuying Qiu; Jing Zhang; Yonghui Zhang; Ying Liu; Yongping Zhao; Qiong Jia; Xiaoduo Fan; Jie Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-17       Impact factor: 5.270

8.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses.

Authors:  Brian J Miller; Andrew Mellor; Peter Buckley
Journal:  Brain Behav Immun       Date:  2012-09-11       Impact factor: 7.217

9.  Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Authors:  Donald C Goff
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

10.  Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups.

Authors:  Jamie Joseph; Colin Depp; Averria Sirkin Martin; Rebecca E Daly; Danielle K Glorioso; Barton W Palmer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2015-09-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.